Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Abstract: The most prevalent Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations were M184V/I (67.3%), K219/Q/E (22.6%) and K65R (21.1%).
Discussion: However, M184V/I (67 (55.8%), p = 0.015), Y188L (9 (100%), p = 0.008) and TAMs (44 (51.8%), p = 0.011) were noted more in subtype A, but the number of occurrence of these mutations could not affect the overall association, therefore the study finds these individual mutation observations statistically irrelevant.
Discussion: The high prevalence of M184V might be attributed to the continued usage of lamivudine as a backbone in all regimens in Uganda and all over sub-Saharan since the presence of this mutation reduces the viral replicative fitness and increases susceptibil
Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naive HIV-1 Subtype C-infected patients in Botswana.
Discussion: Another limitation in this study was the lack of samples with M184V and V106M, making it difficult to draw a conclusion on the performance of PANDAA in detecting V106M and M184V.
Discussion: By using PANDAA, we targeted the most likely mutations to develop to these medications in HIV-1 subtype C, the M184V, K103N and V106M mutations in reverse transcriptase, a targeted and cost-effective approach to genotyping is possible .
Discussion: Firstly, we only examined the most common relevant resistant mutations, V106M, K103N and M184V of the reverse transcriptase<
Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017.
PMID: 31914782
2020
AIDS research and human retroviruses
Abstract: Mutations such as M184V/I (35.4%) in NRTIs and K103N/R/S/T (25.4%), V179D/E/T/Y (18.9%), G190A/E/R/S (13.8%), and Y181C (9.2%) in NNRTIs were common among the HIV-1 URF strains relative to other mutations.
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
PMID: 31516033
2020
AIDS research and human retroviruses
Abstract: M184V was detected pretreatment as a minority variant (9%).
Abstract: In AMBER, the nucleos(t)ide analog reverse transcriptase inhibitor (N(t)RTI) RAM M184I/V was identified in HIV-1 of one participant during D/C/F/TAF treatment.
Abstract: Only one postbaseline M184I/V RAM was observed in HIV-1 of an AMBER participant.
Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy.
Abstract: Resistance mutations were found in most patients (11/17; 64.7%) especially I82F (4/7; 57.1%) and M184V (10/17; 58.8%).
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
PMID: 31774913
2020
The Journal of infectious diseases
Abstract: BACKGROUND: M184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) resistance and increased tenofovir disoproxil fumarate (TDF) susceptibility.
Abstract: CD4 count was lower both at initiation of antiretroviral therapy and at VF in participants who went on to develop M184V/I.
Abstract: CONCLUSIONS: Virus loads were similar in persons with and without M184V/I during VF on a TDF/XTC/NNRTI-containing regimen.
Abstract: In this study, we determined how M184V/I impacts virus load (VL) in patients failing therapy on a TDF/XTC plus nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regimen.
Abstract: In vitro, L74I compensated
Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.
Abstract: The OLA-guided therapy group had pre-ART peripheral blood mononuclear cells evaluated for drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at codons Lys103Asn, Tyr181Cys, Gly190Ala, and to lamivudine at Met184Val, and when at least one drug-resistant codon was detected in a participant's pre-ART specimen, clinicians were directed to prescribe protease inhibitor-based second-line ART.
Result: Testing by OLA detected and CS and/or NGS confirmed 122 mutations in 93 participants at enrollment across both study arms: 61 participants had only mutations conferring resistance to NNRTI, 15 had NNRTI resistance mutations and
Pretreatment HIV drug resistance spread within transmission clusters in Mexico City.
PMID: 31819984
2020
The Journal of antimicrobial chemotherapy
Result: Both M184V and M184I were observed mainly as low-frequency variants in approximately 0.6% of the participants.
Discussion: Moreover, consistent with previous observations, DRMs with low transmission fitness due to high replicative impairment such as M184V/I and K65R were not shared within the Mexican network, and were observed mostly at low within-host frequencies in the study population.
Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.
Method: The OLA detected mutations conferring high-level resistance to NVP/EFV (K103N, Y181C, G190A), 3TC (M184V) and beginning in 2010 to TDF (K65R) using probes optimized for HIV type-1 subtypes A, D and C.
Discussion:
Discussion: An economical and easy to use point of care OLA kit that assesses NNRTI mutations K103N, Y181C, G190A and NRTI mutations M184V and K65R could be used in resource-limited settings to test patients prior to starting EFV-based ART, at virologic failure to guide the choice of 2nd-line ART, or before switching to dolutegravir-based ART.
HIV mutation literature information.
PMID: 
2020
AIDS research and therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT